Related Experiment Video
Updated: Jan 9, 2026

Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System
Published on: July 11, 2025
How AI Transforms Regulatory Submission: Current Clinical Implementation and Future Prospects
Jagdeep T Podichetty1, Anna-Marika Bauer1, Rachel Xu1
1Critical Path Institute, Tucson, Arizona, USA.
None:
Artificial Intelligence (AI) is transforming drug development and regulatory submission by enabling advanced data analytics, predictive modeling and intelligent decision support systems. Beyond efficiency gains, AI establishes a translational bridge between model-informed drug development (MIDD) and clinical implementation, turning regulatory evidence into actionable insights that enhance therapeutic precision and patient outcomes. This perspective paper explores AI's current applications, regulatory integrations, and future prospects in accelerating data-driven, patient-centered drug development.
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Clinical Trials: Overview
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Regulation
Clinical Trials
There are four phases in a clinical trial. A phase one...

